MRI-Targeted vs. Systematic Prostate Biopsy: What Does Each Approach Detect

If your doctor says your PSA is elevated, or something looked suspicious on an exam or scan, the next step is usually a biopsy. Many men don’t realize there is more than one way to do it, and the method can change what gets found and what gets missed.

For decades the standard was a systematic biopsy, which samples the gland in a fixed pattern. MRI-targeted biopsy now plays a major role, using imaging to aim at specific suspicious spots.

Each has real strengths and real blind spots. Knowing them helps you ask better questions, and it helps you understand what a “negative” result does and doesn’t mean.

How a Systematic Biopsy Works

A systematic biopsy, sometimes called a template biopsy, takes roughly 10 to 12 tissue samples, called cores, from standard locations across the prostate. Ultrasound guides the needle, but it usually can’t show the cancer itself. The sampling follows a map rather than a target.

Think of it as sending search parties to a grid. If a tumor sits at one of those points, the biopsy finds it. If it sits between them, or in a hard-to-reach part of the gland, it can slip through.

Systematic biopsy is widely available and can find cancers that never show up on MRI. It also picks up more small, slow-growing cancers that may never cause harm. Our page on how prostate cancer is diagnosed explains how the cores are taken and graded.

How an MRI-Targeted Biopsy Works

An MRI comes first. A radiologist scores any suspicious area on the five-point PI-RADS scale. A score of 4 or 5 signals a likely significant cancer and usually leads to a biopsy of that spot. The doctor then samples the flagged area directly, using one of three methods:

• Cognitive fusion: The doctor studies the MRI and mentally maps it onto the live ultrasound.

• Software fusion: A computer overlays the MRI on the ultrasound image in real time.

• In-bore biopsy: The procedure happens inside the MRI scanner.

You’ll also hear “transrectal” and “transperineal.” These describe the needle’s route: through the rectal wall, or through the skin between the scrotum and anus. Either route works with either biopsy approach.

How the Two Methods Compare

The distinction that matters is clinically significant cancer, usually defined as Gleason Grade Group 2 or higher. These are tumors with real potential to grow and spread. Grade Group 1 cancers often grow so slowly they never need treatment.

	Systematic biopsy	MRI-targeted biopsy	Both combined
How samples are chosen	Fixed pattern across the gland	Aimed at suspicious MRI areas	Both
Significant cancer found	Lower in major trials	Higher in major trials	Generally highest
Low-risk cancer found	Higher	Lower	In between
Depends on MRI quality	No	Yes	Partly
Can find cancer the MRI missed	Yes	No	Yes

The trial that changed practice was PRECISION, published in the New England Journal of Medicine in 2018. It randomized 500 men who had never had a biopsy.

MRI-targeted biopsy found clinically significant cancer in 38% of men, compared with 26% for standard biopsy. It also found low-risk cancer in fewer men (9% vs. 22%). In the MRI group, 28% of men had scans that didn’t suggest cancer and skipped biopsy altogether.

Earlier, the PROMIS study showed that standard ultrasound-guided biopsy caught only 48% of clinically important cancers. A 2019 Cochrane review found the advantage of the MRI pathway was largest for men with a previous negative biopsy.

It rated the overall evidence as low certainty. A French multicenter study, MRI-FIRST, tested both methods in the same men and found that each caught some significant cancers the other missed. That finding is why many urologists still combine them.

What a Negative Biopsy Can Miss

A targeted biopsy only goes where the MRI points. If the scan was poor quality, a lesion was under-scored, or the tumor didn’t show up on imaging, the needle never goes there. Even with a clear target, the needle can land beside the tumor instead of through it.

A systematic biopsy samples only a small fraction of the gland. Tumors toward the front of the prostate or near the apex are the most likely to be missed.

Systematic biopsy can also undergrade a cancer. A later biopsy or surgery then finds a higher grade than the first one showed, so a man may be placed on monitoring when he needed treatment.

A negative biopsy lowers the odds of significant cancer, but it doesn’t end the evaluation. A PSA that keeps rising after a clean biopsy is a reason for repeat MRI, a repeat or combined biopsy, or a referral to a center with more experience.

Transrectal vs. Transperineal Biopsy and Infection Risk

The needle’s route matters for safety. A transrectal biopsy passes through the rectal wall and can carry bacteria into the prostate and bloodstream. Serious infections, including sepsis, are uncommon but real, and antibiotic resistance has made them a growing concern.

A transperineal biopsy goes through the skin and avoids the rectum. The PREVENT trial, led by urologists at Weill Cornell Medicine in New York, randomized 875 men. It found no infections among men who had transperineal biopsy without preventive antibiotics, compared with six infections in the transrectal group.

Any prostate biopsy can also cause bleeding, pain, blood in the urine or semen, and temporary trouble urinating.

What the Guidelines Expect

The American Urological Association and the National Comprehensive Cancer Network support MRI in the diagnostic process and targeted biopsy for men with suspicious findings.

The details, including when to add systematic cores and when to repeat a biopsy after a negative result, are updated regularly. For how screening decisions come first, see our prostate cancer screening protocols.

When a Missed Biopsy Finding Becomes Malpractice

Both methods have known false-negative rates. A cancer that was missed on one biopsy and found later is not, by itself, proof of negligence.

A New York malpractice claim generally requires showing that a provider departed from accepted standards of care, and that the departure was a substantial factor in causing harm. Situations that raise legitimate questions include:

• A PI-RADS 4 or 5 lesion that was never biopsied

• A visible lesion the radiologist misread or never reported

• A sample the pathologist misgraded

• A negative biopsy followed by no further workup while PSA kept climbing

• Biopsy results that were never communicated to the patient

Questions about informed consent can also arise if biopsy options and infection risks were never explained.

Care is judged by the standards in place when it was given. A systematic-only biopsy in 2014, before PRECISION, is measured against 2014 practice. A biopsy today that ignores a suspicious MRI is measured against today’s.

Causation is usually the hardest part. Urology and oncology experts must show that an earlier or better biopsy would likely have found the cancer at a more treatable stage. New York also requires a certificate of merit before a malpractice suit can be filed.

Talk With a New York Cancer Lawyer

If you were told your biopsy was clear and prostate cancer was found later, or a suspicious MRI or abnormal result was never acted on, you may have options.

Porter Law Group represents patients and families across New York, with offices in Albany, Buffalo, New York City, Rochester, and Syracuse.

Our New York cancer lawyers work with radiology, pathology, and urology experts to review the imaging, the biopsy slides, and the follow-up that should have happened. For more on these claims, see our prostate cancer malpractice overview and our results in delayed cancer diagnosis cases.

Call 833-888-LATE, email info@porterlawteam.com, or request a free case evaluation.

Attorney advertising. This article provides general information and is not legal or medical advice. Prior results do not guarantee a similar outcome. Filing deadlines depend on the facts of each case.

Frequently Asked Questions

Is MRI-targeted biopsy better than systematic biopsy?

For finding aggressive cancer, usually yes. In the PRECISION trial, MRI-targeted biopsy found clinically significant prostate cancer in 38% of men, compared with 26% for standard systematic biopsy, and it found fewer low-risk cancers. Systematic biopsy can still catch tumors the MRI misses, which is why many urologists combine both methods.

Can a prostate biopsy miss cancer?

Yes. A systematic biopsy samples only a small part of the gland, so tumors near the front or apex can be missed or undergraded. A targeted biopsy misses cancer the MRI didn’t show and can land beside a tumor. A negative biopsy lowers the risk but doesn’t rule out cancer, especially if PSA keeps rising.

Is a transperineal biopsy safer than a transrectal biopsy?

For infection risk, the evidence favors it. The PREVENT trial, led by Weill Cornell Medicine in New York, randomized 875 men. It found no infections after transperineal biopsy done without preventive antibiotics, compared with six infections after transrectal biopsy. An earlier report from the trial found both routes detected significant cancer at similar rates.

What should happen after a negative prostate biopsy if my PSA keeps rising?

A rising PSA after a clean biopsy shouldn’t be ignored. Depending on your history, reasonable next steps include a repeat or first-time prostate MRI, a repeat biopsy that combines targeted and systematic cores, or a second opinion at an experienced center. Ask your urologist to put the follow-up plan, and who schedules it, in writing.

Can I sue if a prostate biopsy missed my cancer in New York?

Possibly. A missed cancer alone isn’t negligence, but claims can arise when a suspicious MRI lesion was never biopsied, a sample was misgraded, or a rising PSA went unaddressed after a negative biopsy. Under CPLR 214-a, these claims generally must be filed within two and a half years of discovery, with a seven-year outer limit.